{"id":19688,"date":"2025-03-10T19:47:29","date_gmt":"2025-03-10T23:47:29","guid":{"rendered":"https:\/\/leasonellis.com\/?p=19688"},"modified":"2025-03-10T19:53:04","modified_gmt":"2025-03-10T23:53:04","slug":"ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation","status":"publish","type":"post","link":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/","title":{"rendered":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":19689,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8,15],"tags":[22],"class_list":["post-19688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-articles","category-our-articles-patent-law","tag-patent-law"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Leason Ellis\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T23:47:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T23:53:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Leason Ellis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leason Ellis\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/\"},\"author\":{\"name\":\"Leason Ellis\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/#\\\/schema\\\/person\\\/94935f87f271135b29276d0e5850c936\"},\"headline\":\"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation\",\"datePublished\":\"2025-03-10T23:47:29+00:00\",\"dateModified\":\"2025-03-10T23:53:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/\"},\"wordCount\":10,\"image\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/leasonellis.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png\",\"keywords\":[\"Patent Law\"],\"articleSection\":[\"Articles\",\"Patent Law Articles\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/\",\"url\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/\",\"name\":\"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/leasonellis.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png\",\"datePublished\":\"2025-03-10T23:47:29+00:00\",\"dateModified\":\"2025-03-10T23:53:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/#\\\/schema\\\/person\\\/94935f87f271135b29276d0e5850c936\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/leasonellis.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png\",\"contentUrl\":\"https:\\\/\\\/leasonellis.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/\",\"name\":\"Leason Ellis\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/#\\\/schema\\\/person\\\/94935f87f271135b29276d0e5850c936\",\"name\":\"Leason Ellis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g\",\"caption\":\"Leason Ellis\"},\"sameAs\":[\"https:\\\/\\\/leasonellis.com\"],\"url\":\"https:\\\/\\\/leasonellis.com\\\/ja\\\/author\\\/leasonellis\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/","og_locale":"ja_JP","og_type":"article","og_title":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis","og_url":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/","og_site_name":"Leason Ellis","article_published_time":"2025-03-10T23:47:29+00:00","article_modified_time":"2025-03-10T23:53:04+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png","type":"image\/png"}],"author":"Leason Ellis","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"Leason Ellis","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#article","isPartOf":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/"},"author":{"name":"Leason Ellis","@id":"https:\/\/leasonellis.com\/ja\/#\/schema\/person\/94935f87f271135b29276d0e5850c936"},"headline":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation","datePublished":"2025-03-10T23:47:29+00:00","dateModified":"2025-03-10T23:53:04+00:00","mainEntityOfPage":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/"},"wordCount":10,"image":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png","keywords":["Patent Law"],"articleSection":["Articles","Patent Law Articles"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/","url":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/","name":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation - Leason Ellis","isPartOf":{"@id":"https:\/\/leasonellis.com\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#primaryimage"},"image":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png","datePublished":"2025-03-10T23:47:29+00:00","dateModified":"2025-03-10T23:53:04+00:00","author":{"@id":"https:\/\/leasonellis.com\/ja\/#\/schema\/person\/94935f87f271135b29276d0e5850c936"},"breadcrumb":{"@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#primaryimage","url":"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png","contentUrl":"https:\/\/leasonellis.com\/wp-content\/uploads\/2025\/03\/IP-Due-Diligence-in-the-Pharmaceutical-Industry-Evaluating-Hatch-Waxman-Litigation.png","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/leasonellis.com\/ja\/ip-due-diligence-in-the-pharmaceutical-industry-evaluating-hatch-waxman-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/leasonellis.com\/ja\/"},{"@type":"ListItem","position":2,"name":"IP Due Diligence in the Pharmaceutical Industry: Evaluating Hatch-Waxman Litigation"}]},{"@type":"WebSite","@id":"https:\/\/leasonellis.com\/ja\/#website","url":"https:\/\/leasonellis.com\/ja\/","name":"Leason Ellis","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leasonellis.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/leasonellis.com\/ja\/#\/schema\/person\/94935f87f271135b29276d0e5850c936","name":"Leason Ellis","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/77b219f8a0abf4a7bef4a95cb5fa9c4ccf6d020345b4667969278182cb311b6b?s=96&d=mm&r=g","caption":"Leason Ellis"},"sameAs":["https:\/\/leasonellis.com"],"url":"https:\/\/leasonellis.com\/ja\/author\/leasonellis\/"}]}},"_links":{"self":[{"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/posts\/19688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/comments?post=19688"}],"version-history":[{"count":0,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/posts\/19688\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/media\/19689"}],"wp:attachment":[{"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/media?parent=19688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/categories?post=19688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leasonellis.com\/ja\/wp-json\/wp\/v2\/tags?post=19688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}